FDA Designations for Therapeutics and Their Impact on Drug Development and Regulatory Review Outcomes
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
FDA Designations for Therapeutics and Their Impact on Drug Development and Regulatory Review Outcomes
Authors
Keywords
-
Journal
CLINICAL PHARMACOLOGY & THERAPEUTICS
Volume 97, Issue 1, Pages 29-36
Publisher
Wiley
Online
2015-02-12
DOI
10.1002/cpt.1
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Era Of Faster FDA Drug Approval Has Also Seen Increased Black-Box Warnings And Market Withdrawals
- (2014) Cassie Frank et al. HEALTH AFFAIRS
- Clinical Trial Evidence Supporting FDA Approval of Novel Therapeutic Agents, 2005-2012
- (2014) Nicholas S. Downing et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Drug Development and FDA Approval, 1938–2013
- (2014) Jonathan J. Darrow et al. NEW ENGLAND JOURNAL OF MEDICINE
- New FDA Breakthrough-Drug Category — Implications for Patients
- (2014) Jonathan J. Darrow et al. NEW ENGLAND JOURNAL OF MEDICINE
- Multidrug-Resistant Tuberculosis and Culture Conversion with Bedaquiline
- (2014) Andreas H. Diacon et al. NEW ENGLAND JOURNAL OF MEDICINE
- An Improved Approach To Measuring Drug Innovation Finds Steady Rates Of First-In-Class Pharmaceuticals, 1987–2011
- (2013) Michael Lanthier et al. HEALTH AFFAIRS
- The Food and Drug Administration Amendments Act and Postmarketing Commitments
- (2013) Kevin Fain et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- The most transformative drugs of the past 25 years: a survey of physicians
- (2013) Aaron S. Kesselheim et al. NATURE REVIEWS DRUG DISCOVERY
- Development Times, Clinical Testing, Postmarket Follow-up, and Safety Risks for the New Drugs Approved by the US Food and Drug Administration
- (2013) Thomas J. Moore et al. JAMA Internal Medicine
- Randomized Pilot Trial of Eight Weeks of Bedaquiline (TMC207) Treatment for Multidrug-Resistant Tuberculosis: Long-Term Outcome, Tolerability, and Effect on Emergence of Drug Resistance
- (2012) A. H. Diacon et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- New Drugs and Safety
- (2012) Joel Lexchin ARCHIVES OF INTERNAL MEDICINE
- Regulatory Review of Novel Therapeutics — Comparison of Three Regulatory Agencies
- (2012) Nicholas S. Downing et al. NEW ENGLAND JOURNAL OF MEDICINE
- Communicating Uncertainties About Prescription Drugs to the Public
- (2011) Lisa M. Schwartz ARCHIVES OF INTERNAL MEDICINE
- Characteristics of Clinical Trials to Support Approval of Orphan vs Nonorphan Drugs for Cancer
- (2011) Aaron S. Kesselheim JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Accelerated Approval of Oncology Products: The Food and Drug Administration Experience
- (2011) John R. Johnson et al. JNCI-Journal of the National Cancer Institute
- Pivotal studies of orphan drugs approved for neurological diseases
- (2009) Jun Mitsumoto et al. ANNALS OF NEUROLOGY
- Drug-Review Deadlines and Safety Problems
- (2008) Daniel Carpenter et al. NEW ENGLAND JOURNAL OF MEDICINE
- The risk we bear: The effects of review speed and industry user fees on new drug safety
- (2007) Mary K. Olson JOURNAL OF HEALTH ECONOMICS
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started